AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior listings of claims presented in the application.

1. (Currently amended) A compound of formula (I),



(I)

and its tautomeric forms, its stereoisomers, and its pharmaceutically acceptable salts,

wherein R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} may be the same or different and each independently represent hydrogen, halogen, perhaloalkyl, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups ~~such as~~ selected from the group consisting of linear or branched (C_1-C_{12})alkyl, (C_2-C_{12})alkenyl, (C_2-C_{12})alkynyl, (C_3-C_7)cycloalkyl, (C_3-C_7)cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C_1-C_{12})alkoxy, cyclo(C_3-C_7)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, heterocyclylalkoxycarbonyl, heteroaryloxycarbonyl, hydroxyalkyl, aminoalkyl,

monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkylamidino, alkylguanidino, dialkylguanidino, hydrazino, and hydroxylamino; or the adjacent groups ~~like~~ R_1 and R_2 or R_2 and R_3 or R_3 and R_4 or R_5 and R_6 or R_6 and R_7 or R_7 and R_8 together with carbon atoms to which they are attached may form a 5, 6, or 7 membered ring, which may further optionally contain one or more double bonds and/or one or more heteroatoms ~~such as~~ selected from the group consisting of the group "Oxygen", "Nitrogen", "Sulfur" ~~or~~ and "Selenium" ~~and combinations of double bond and heteroatoms~~; or R_9 and R_{10} or R_{11} and R_{12} together represent double bond attached to "Oxygen" or "Sulfur"; or R_9 and R_{10} or R_{11} and R_{12} together with the carbon atoms to which they are attached may form a 3, 4, 5, or 6 membered ring, which may further optionally contain one or more double bonds, and/or one or more heteroatoms ~~such as~~ selected from the group consisting of the group "Oxygen", "Nitrogen", "Sulfur" ~~or~~ and "Selenium," ~~as above defined~~;

R_{13} and R_{14} may be the same or different and each independently represents hydrogen, substituted or unsubstituted groups ~~such as~~ selected from the group consisting of linear or branched (C_1-C_{12})alkyl, (C_2-C_{12})alkenyl, (C_2-C_{12})alkynyl, (C_2-C_{12})alkanoyl (C_3-C_7)cycloalkyl, (C_3-C_7)cycloalkenyl, bicycloalkyl, bicycloalkenyl, aryl, aralkyl, heteroaryl, ~~or~~ and heterocyclylalkyl; or R_{13} and R_{14} along with the nitrogen atom, may form a 3, 4, 5, 6 or 7-membered heterocyclic ring, wherein the ring may be further substituted, and it may have either one, two or three double bonds or "additional heteroatoms", ~~as defined above~~; and

"n" is an integer ranging from 1 to ~~8~~ 7.

2. (Currently amended) A compound according to Claim 1, which is selected from the group consisting of:

6-(2-N,N-Dimethylaminoethyl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Bromo-6-(2-N,N-dimethylaminoethyl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Chloro-6-(2-N,N-dimethylaminoethyl)-benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-4-fluorobenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-4-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-4-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide hydrochloride salt;

6-(2-N,N-Dimethylaminoethyl)-4-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide maleate

salt;

6-(2-N,N-Dimethylaminoethyl)-4-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide D,L-malic acid salt;

6-(2-N,N-Dimethylaminoethyl)-4-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide oxalate salt;

6-(2-N,N-Dimethylaminoethyl)-4-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide citrate salt;

6-(2-N,N-Dimethylaminoethyl)-4-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-8-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Bromo-6-(2-N,N-dimethylaminoethyl)-8-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Chloro-6-(2-N,N-dimethylaminoethyl)-8-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-4-fluoro-8-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-4-methyl-8-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-4,8-dimethoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-2-ethylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

2-Chloro-6-(2-N,N-dimethylaminoethyl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

2,4-Dichloro-6-(2-N,N-dimethylaminoethyl)-benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

2,3-Dichloro-6-(2-N,N-dimethylaminoethyl)-benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

5-Chloro-6-(2-N,N-dimethylaminoethyl)-2-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

2,4,5-Trichloro-6-(2-N,N-dimethylaminoethyl)-benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-2,4-difluorobenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-dimethylaminoethyl)-4-fluoro-8-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

2,4-Difluoro-6-(2-N,N-dimethylaminoethyl)-8-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-2-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-2,8-dimethoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-N,N-Dimethylaminoethyl)-8-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(3-N,N-Dimethylamino-1-hydroxyprop-1-yl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Bromo-6-(3-N,N-Dimethylamino-1-hydroxyprop-1-yl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(3-N,N-Dimethylamino-1-hydroxyprop-1-yl)-8-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(3-N,N-Dimethylamino-1-hydroxyprop-1-yl)-8-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Bromo-6-(3-N,N-dimethylamino-1-hydroxyprop-1-yl)-8-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-[2-(4-Methylpiperazin-1-yl)ethyl]benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-[2-Morpholin-4-ylethyl]benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-Pyrrolidin-1-ylethyl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-Piperidin-1-yl)ethyl]benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Bromo-6-[2-morpholin-4-ylethyl]benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Bromo-6-(2-pyrrolidin-1-ylethyl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Bromo-6-[2-(4-methylpiperazin-1-yl)ethyl]benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(3-(Piperidin-1-yl)-1-hydroxyprop-1-yl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(3-(Piperidin-1-yl)-1-hydroxyprop-1-yl)-8-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Bromo-6-(3-(piperidin-1-yl)-1-hydroxyprop-1-yl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Bromo-6-(3-(piperidin-1-yl)-1-hydroxyprop-1-yl)-8-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(3-(Pyrrolidin-1-yl)-1-hydroxyprop-1-yl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(3-(Pyrrolidin-1-yl)-1-hydroxyprop-1-yl)-8-methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-(N,N-Diethylamino)-2-methylethyl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-(N,N-Dimethylamino-1-hydroxy-1-yl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Bromo-6-(2-(N,N-Dimethylamino-1-hydroxy-1-yl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-(N,N-Dimethylaminoethyl)-2,4-difluoro-8-~~M~~methoxybenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

6-(2-(N,N-Dimethylamino-2-methylethyl)benzo[d]isothiazolo[3,2-a]indol-S,S-dioxide;

4-Chloro-6-(2-(N,N-Dimethylaminoethyl)-8-methylbenzo[d]isothiazolo[3,2-a]indol-S,S-dioxide; and

8-(2-(N,N-Dimethylaminoethyl)benzo[d]isothiazolo[3,2-a]benzo(g)indol-S,S-dioxide,

or its stereoisomers, its N-oxides, ~~and~~ or its pharmaceutically acceptable salts.

3. (Currently amended) A pharmaceutical composition comprising either of a pharmaceutically acceptable carrier, diluent/s, excipient/s or solvents along with a therapeutically

effective amount of a compound according to Claim 1, its tautomeric forms, its stereoisomers, its geometric forms, its N-oxides, ~~and~~ or its pharmaceutically acceptable salts.

4. (Currently Amended) A pharmaceutical composition according to Claim 3, in the form of a tablet, capsule, powder, lozenges, suppositories, syrup, solution, suspension or injectable, administered ~~in,~~ as a single dose or multiple dose units.

5-25. (Canceled)

26. (Currently amended) ~~Novel intermediates~~ Intermediates of formula **(III)** are represented as given below,



(III)

wherein R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} may be the same or different and each independently represent hydrogen, halogen, perhaloalkyl, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups ~~such as~~ selected from the group consisting of linear or branched (C_1-C_{12})alkyl, (C_2-C_{12})alkenyl, (C_2-C_{12})alkynyl, (C_3-C_7)cycloalkyl, (C_3-C_7)cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C_1-C_{12})alkoxy, cyclo(C_3-C_7)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, heterocyclylalkoxycarbonyl, heteroaryloxycarbonyl, hydroxyalkyl, aminoalkyl,

monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkylamidino, alkylguanidino, dialkylguanidino, hydrazino, and hydroxylamino; or the adjacent groups ~~like~~ R_1 and R_2 or R_2 and R_3 or R_3 and R_4 or R_5 and R_6 or R_6 and R_7 or R_7 and R_8 together with carbon atoms to which they are attached may form a 5, 6, or 7 membered ring, which may further optionally contain one or more double bonds and/or one or more heteroatoms ~~such as~~ selected from the group consisting of the group "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; or R_9 and R_{10} or R_{11} and R_{12} together represent double bond attached to "Oxygen" or "Sulfur"; or R_9 and R_{10} or R_{11} and R_{12} together with the carbon atoms to which they are attached may form a 3, 4, 5, or 6 membered ring, which may further optionally contain one or more double bonds, and/or one or more heteroatoms ~~such as~~ selected from the group consisting of the group "Oxygen", "Nitrogen", "Sulfur" ~~or~~ and "Selenium"~~, as above defined~~;

"n" is an integer ranging from 1 to 8.

27-29. (Canceled)

30. (Previously presented) The compound of claim 1, wherein n is 1 to 4.

31. (Currently amended) The ~~novel~~ intermediates of claim 26, wherein n is 1 to 4.